May 23, 2016 — In a guideline update published last week, the American College of Cardiology, American Heart Association and Heart Failure Society of America detail the groups’ recommendations for the use of two new heart failure medications.
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates and a greater risk of recurrent heart failure after transcatheter aortic valve replacement (TAVR).
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) achieves equivalent clinical and angiographic outcomes to intravascular ultrasound (IVUS)-guided PCI at 12 months.
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk of stroke. These strokes resulting from the embolization of left atrial appendage (LAA) thrombi account for up to 25 percent of the 700,000 cerebrovascular strokes annually in the United States.[1] Many experts believe the LAA is the culprit in a much higher percentage of strokes.
If you enjoy this content, please share it with a colleague
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision support tool to assist physicians and patients with decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation.
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based approach from within the left ventricle.
